Beijing Shenogen Pharma Group Ltd.

Hongxia Ding

Kun Meng

Jin Li

Shu Li

Ya Tuo

Yueqiu Shen

The present invention provides the use of Icaritin for the preparation of a composition for treating cancer, wherein the composition is orally administered to a patient at least one cycle, each cycle comprising a continuous 28-day dosing schedule, in which Icaritin is administered at least once daily, at a dosage of 400-1800 mg daily. The patients treated with Icaritin according to the present method receive better treatment, with reduced adverse effects.

Use of icaritin for the preparation of composition for treating cancer

The present invention is directed to chromenone compounds of formula (I), pharmaceutically acceptable salts, prodrugs thereof, and the composition comprising the compounds or the like. They can be used to modulating the function of estrogen receptor ER-&#x3b1;36 preventing and/or treating the estrogen related diseases, such as breast cancer, leukemia, liver cancer and etc.

Synthesis of polyhydroxy chromenone compounds and their anti-tumor effects

The present invention provides a kind of benzopyrone compounds having a structure of formula (I) and the pharmaceutically acceptable salts or prodrugs thereof, and the pharmaceutical compositions containing such compounds, which can be used to regulate the novel estrogen receptor ER-a36, and prevent and/or treat the related diseases mediated by the ER-a36 receptor, such as cancers, etc.

Growing community of inventors

Beijing, China

Hongxia Ding